Targeted Treatment for Severe Episodic Headaches

Degran is commonly used across conditions presenting with acute episodes of severe vascular headaches, and may be part of symptomatic management for conditions like migraine and cluster headache, which present with symptoms related to heightened physiological activity. This combination preparation is generally applied in clinical settings that involve acute or unstable symptom patterns, particularly when symptoms may intensify temporarily. The medication is applied across domains where additional symptomatic support is needed during recurrent or episodic manifestations. It is considered relevant in conditions where symptoms may intensify temporarily, providing short-term symptomatic assistance when required.

Relief from Associated Disabling Symptoms

The preparation is used for managing symptom clusters that may become intense or disruptive, extending the benefit beyond the core pain. This is relevant for managing symptoms that interfere with daily comfort, and may assist with associated manifestations such as nausea and vomiting. It is commonly used to help with symptom clusters that may become intense or disruptive, contributing to easing the overall symptom load. This may help provide supportive relief when symptoms interfere with routine activities, supporting general well-being during symptomatic phases.

Quick Fact: Relief for Severe, Episodic Head Pain

Regulatory References

1. NIH MedlinePlus overview

Use of Degran (Ergotamine and Caffeine) is strictly defined by regulatory authorities and is generally restricted to adults (18 years and older). Official labeling specifies numerous populations who must not use the medicine due to the risk of severe vascular complications.

---

Absolute Contraindications

The medicine is absolutely contraindicated in individuals with pre-existing vascular and systemic conditions, including Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), history of Myocardial Infarction, and Uncontrolled Hypertension. Use is also prohibited in cases of severe hepatic or severe renal impairment and during systemic infection like Sepsis. The medicine must not be used during pregnancy in any trimester. Co-administration with specific potent CYP3A4 inhibitors is also strictly forbidden.

Population Restrictions

Use is not recommended for the pediatric population (under 18 years) as safety and efficacy have not been established. Similarly, the medicine is not recommended for use in older adults (over 65) or in women who are breastfeeding, as the active compound is known to pass into breast milk.

Degran Interactions with other medicines and products

The interaction profile for this product is characterized by clinically significant risks involving both how the body handles the medicine and its direct effects on the body's systems.

Contraindicated Combinations (High Risk):

• Potent CYP3A4 Inhibitors: Co-administration with potent inhibitors of the CYP3A4 enzyme is contraindicated. This includes specific antiretroviral, antifungal, and antibiotic medications (e.g., ritonavir, clarithromycin, ketoconazole). The mechanism is a significant pharmacokinetic interaction leading to dangerously elevated concentrations of Degran, which can cause acute ergot toxicity characterized by severe vasospasm, peripheral ischemia, and potential cerebral ischemia.
• Triptans: Other vasoconstrictive migraine medications (triptans, such as almotriptan and eletriptan) are contraindicated. The mechanism is a pharmacodynamic synergism leading to an additive risk of vasospasm.
• Nitrates: Combinations with organic nitrates are contraindicated due to potential pharmacodynamic antagonism.

Major Interaction Categories:

• Vasoconstrictors: Degran's own vasoconstricting activity may be increased by certain blood pressure medications (e.g., beta-blockers) and other vasoconstrictive agents, increasing the risk of hypertension and decreased blood flow.
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Combining with NSAIDs may increase the risk or severity of hypertension.

Other Factors:

• Grapefruit Juice: Intake is discouraged as it may inhibit Degran's metabolism (CYP3A4), potentially increasing its blood concentration and toxicity risk.
• A separation time of at least 24 hours is required between taking Degran and a triptan.

Dual Action on Cranial Vessels and Nerves

The primary mechanism involves Ergotamine acting as a partial agonist on non-selective sites, including specific serotonin receptors (5 -HT1 B/1 D) and alpha-adrenergic receptors. These interactions occur at the smooth muscle of extracerebral blood vessels and the peripheral trigeminal nerve endings. This dual engagement initiates a cascade that achieves sustained vasoconstriction of the cranial vessels while simultaneously inhibiting the release of neuropeptides associated with afferent nociceptive signaling (like CGRP) from the nerves, thereby inhibiting afferent signal transmission within the trigeminal system.

Adjuvant Enhancement of Pharmacological Effect

The second component, Caffeine, contributes mechanistically by acting as a competitive antagonist at adenosine receptors, which intrinsically induces cerebral vasoconstriction that is additive to the primary component’s vascular effect. Caffeine also acts as a mechanistic adjuvant by increasing the rate and extent of Ergotamine’s oral absorption. This enhancement leads to an acceleration of drug concentration required for receptor activation by rapidly ensuring effective concentrations of the primary ingredient are available to modulate its biological targets.

Limitations of Non-Selective Modulation

The mechanism is constrained by Ergotamine’s non-selective binding profile across multiple receptor families. This interaction results in vasoconstriction that is not strictly limited to the cranial vasculature but also engages alpha-adrenergic and other receptors systemically, which defines the boundaries of the drug’s mechanistic application.

How to use Degran: Administration Guidelines

The usage protocol for Degran (ergotamine 1 mg / caffeine 100 mg oral tablets) is established for the acute management of vascular headaches. The route for this preparation is oral ingestion, typically taken with water, although a rectal suppository formulation is also available for the combination product.

Labeled Dosing and Administration Schedule

The administration regimen establishes clear, quantitative limits.

Administration Parameter	Parameters
Initial Dose (Oral)	2 tablets (2 mg Ergotamine / 200 mg Caffeine) at the first sign of an attack.
Subsequent Dose	1 additional tablet every 30 minutes, if necessary.
Maximum per Attack (24 hrs)	Not to exceed 6 tablets (6 mg Ergotamine / 600 mg Caffeine).
Maximum Weekly Dose (7 days)	Not to exceed 10 tablets (10 mg Ergotamine / 1000 mg Caffeine).

These dose ceilings must be observed. The medicine is designated exclusively for acute, intermittent use, and its chronic, daily administration is prohibited.

Contextual Use and Restrictions

Administration should occur at the earliest sign of an attack. Patients are instructed to take the tablets with water. Furthermore, specific usage constraints include avoiding the consumption of grapefruit or grapefruit juice during the treatment period. Use is prohibited in patients with renal or hepatic impairment and safety has not been established for the pediatric population. These parameters define the standardized approach to using the medicine.

Research evidence / Overview of studies for Degran

This section provides an overview of the types of clinical studies and research used in the evaluation of the ergotamine/caffeine combination, describing what the studies research examined and what findings describe patterns observed in the studies.

Evidence for Use in Acute Vascular Headaches

The clinical investigation for Degran was studied for its role in conditions characterized by fluctuating or episodic manifestations, such as acute migraine and other vascular headaches. The research consists primarily of Randomized Controlled Trials (RCTs), many of which are older, double-blind designs, along with systematic reviews that synthesize existing trial data.

What researchers studied: These trials monitored outcomes related to physical discomfort, primarily by researching exploring short-term symptom changes in headache pain intensity at defined intervals, such as one and two hours post-dose. Researchers also examined patient-reported outcomes describing episodic or acute changes in associated symptoms, including nausea, vomiting, and sensitivity to light (photophobia) and sound (phonophobia). Studies focusing on episodes where symptoms become more noticeable also measured the rate at which headache pain returned (recurrence rate) within the short-term observation period of 24 to 48 hours.

What the studies reported: The findings describe patterns observed in the studies related to changes in pain intensity measurements within the short observation periods. Comparative evidence research describes patterns related to observed differences when the combination was evaluated in trials against either an inactive treatment (placebo) or against other active acute headache therapies. The research describes changes measured during the study period for the accompanying symptoms.

Research Base for Non-Headache Specialized Indications

The combination was evaluated in a separate, specialized research context involving conditions related to systemic or functional imbalance, such as neurogenic orthostatic hypotension (a drop in blood pressure upon standing).

What researchers studied: This evidence consists of a limited number of acute controlled studies where the combination was observed in limited cohorts of adults with severe autonomic failure. Researchers monitored physiological strain or stress by measuring acute changes in blood pressure, particularly when standing. The findings help contextualize how patients reported their experience under highly controlled, acute conditions.

Consistency and Gaps in the Research Record

Overall, the evidence quality varies across studies, with many foundational trials for acute headache relief being older. Reviewers and expert panels recognize that the evidence contributes to understanding symptom patterns but note that comparative evidence is lacking for some comparisons against other acute therapies.

The limited scale and short duration of studies for non-headache specialized uses mean that the certainty remains low in those areas of investigation. The overall evidence highlights what is known — and what is still uncertain — about the full research landscape for the combination.

Key Studies & References

1. The fixed-dose combination of ergotamine and caffeine for the treatment of acute migraine attacks
2. Ergotamine and Caffeine (MedlinePlus Drug Information)

Common questions about Degran (FAQ)

---

Q: Is Degran a brand-name drug, or is a generic version available?

The medicine is available under both specific brand names, such as Cafergot or Migergot, and its generic designation, which is ergotamine tartrate and caffeine tablets. Regulatory documents list the availability of these different formulations.

---

Q: How is Degran different from other medicines used for the same condition?

Degran's primary difference is its fixed-dose combination of an ergot derivative and caffeine. Official warnings describe its mechanism of action as distinct from other acute migraine treatments, such as triptans. Co-administration with triptans is strictly contraindicated due to the risk of additive side effects.

---

Q: Are there any known drug-to-drug interactions to be aware of when using Degran?

Yes, regulatory documents emphasize the risk of serious drug-to-drug interactions. It is strictly contraindicated with potent CYP3A4 inhibitors, which include certain antibiotics and antifungals. Co-administration with other vasoconstrictors, such as triptans, is strictly contraindicated due to the severe risk of complications.

---

Q: Does Degran interact with alcohol?

Official guidance suggests caution regarding the concurrent use of alcohol while using this medicine. Patient guidance indicates that alcohol intake may increase the risk of dizziness or other adverse reactions associated with the medication.

---

Q: Are there special considerations for older adults using Degran?

Official prescribing information states that using this medicine in older adults (the geriatric population) requires caution. This is due to a potentially increased susceptibility to cardiovascular complications and other adverse reactions compared to younger adults.

---

Q: Has Degran been studied for long-term safety and efficacy?

Regulatory warnings state that this medicine is designated for acute, intermittent use only. Chronic, daily administration is expressly prohibited because long-term continuous use carries a risk of serious complications, including rare fibrotic changes in the heart and lungs.

---

Q: Do I have to take Degran with food, or can I take it on an empty stomach?

According to the official administration instructions, the tablets can be taken either with or without food. Official information states that the medicine may be taken regardless of food status.

---

Q: Can Degran be taken at the same time as all other daily medications?

Due to the risk of serious interactions, the concurrent use of any other medicines, including over-the-counter products, requires careful review by a healthcare provider. The official label lists numerous contraindicated and major interaction categories.

---

Q: Will Degran still work if it is taken inconsistently?

This medicine is intended for acute use. The labeling instructs the medicine to be taken as soon as symptoms of an attack start. If the medicine is not working as expected, the maximum dose must not be exceeded, and consultation with a healthcare provider is recommended to discuss changes in effectiveness.

---

Q: Can Degran cause unintended weight gain or weight loss?

The adverse reaction data has reported cases of loss of appetite, which could potentially lead to weight loss. Patients who notice changes in appetite or weight should discuss this with their healthcare provider. Official patient guidance suggests consulting a healthcare provider if a change in appetite continues or becomes severe.

---

Q: Is feeling tired or dizzy a known side effect of Degran?

Yes, dizziness, lightheadedness, and general weakness have been reported as known adverse reactions in the official safety profile for this medicine.

---

Q: What should I do if a minor side effect of Degran is bothersome?

Official guidance recommends that patients consult with a healthcare professional if any minor side effects are bothersome or persist. This ensures proper evaluation of the symptoms.

---

Q: How long does it typically take before Degran starts to have an effect?

Clinical pharmacology information indicates that the inclusion of caffeine is designed to accelerate the absorption of ergotamine. This combined action contributes to the speed of the absorption process, which is necessary for the rapid onset of action observed in studies.

---

Q: What is the process for stopping Degran after long-term use?

Regulatory warnings indicate that abrupt discontinuation, especially after chronic or indiscriminate use, has been associated with withdrawal symptoms, primarily a rebound headache. Because of this risk, official guidance indicates that any decision to stop the medicine should be managed by a healthcare provider.

---

Q: Where can I find summaries of the official research or regulatory documents for Degran?

Official prescribing information and safety data can be found on regulatory websites like the FDA’s DailyMed. You can also find patient-specific summaries of this information on government sites like MedlinePlus.

---

Q: Is it true that generic Degran is less effective than the brand name?

Generic versions of medications must meet strict regulatory requirements. For generic Degran to be approved, it must demonstrate that it is bioequivalent to the original brand-name product, meaning it works the same way in the body.

---

Q: What happens if I forget or miss a dose of Degran?

Official patient guidance provides specific instructions for taking a missed dose, stating it should be taken as soon as it is remembered. If it is almost time for the next scheduled dose, the missed one should be skipped, and the regulatory instructions forbid taking extra medicine to make up for a missed dose.

---

Q: Is Degran considered a controlled substance?

No, official regulatory bodies do not classify this specific medicine as a controlled substance. It is designated as a prescription-only drug.

---

Q: Is Degran known to be addictive or habit-forming?

Official warnings state that the medicine may be habit-forming, particularly if it is used chronically or for long periods. The official maximum dosage should not be exceeded. If a patient feels the medicine is not working effectively, consultation with a healthcare provider is recommended.

---

Q: Do official guidelines provide information about Degran and driving or operating machinery?

Yes, official guidance states that patients should avoid driving or operating machinery until they understand how the medicine affects them. This warning is due to the reported risk of dizziness and lightheadedness.

---

Q: What is the half-life of Degran, and why is this relevant?

The half-life of ergotamine, one of the active components, is stated in clinical pharmacology documents as approximately two hours. This pharmacokinetic information is used by healthcare professionals to establish the proper time interval between doses for acute use.

---

Q: Is it normal to feel a change in appetite after starting Degran?

Loss of appetite has been reported in the adverse reaction data, though its frequency is not always known. Official patient guidance suggests consulting a healthcare provider if this side effect continues or becomes severe.

---

Q: What is the risk of an allergic reaction to Degran?

Allergic reactions, including localized swelling and itching, have been reported in the official safety profile. The tablets may also contain a specific dye (like tartrazine) that can trigger allergic reactions, particularly in people with aspirin sensitivity.

How to Store and Dispose of Degran

Official labeling mandates specific conditions for storing and disposing of Degran (ergotamine and caffeine) tablets to maintain stability and ensure safety.

Required Storage and Handling

Storage Component	Regulatory Mandate
Temperature	Store at controlled room temperature, between 20 C and 25 C (68 F and 77 F).
Protection	Keep away from freezing, excessive heat, direct light, and moisture.
Packaging	Keep in the original container and ensure it is tightly closed.
Child Safety	Must be stored out of the sight and reach of children; safety caps should be locked.

Disposal Instructions

Unused or expired tablets should be disposed of using a drug take-back program as the primary, preferred method. If a take-back program is unavailable, the product may be mixed with an unappealing substance, sealed in a container, and disposed of in the household trash. The medicine should not be flushed down a sink or toilet. All personal information must be scratched out from the label before discarding the container.